Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2021

Feb 14, 2022

SELL
$3.43 - $4.65 $15,832 - $21,464
-4,616 Closed
0 $0
Q3 2021

Nov 09, 2021

BUY
$3.1 - $4.32 $9,944 - $13,858
3,208 Added 227.84%
4,616 $19,000
Q2 2021

Aug 13, 2021

SELL
$4.45 - $9.91 $8,917 - $19,859
-2,004 Reduced 58.73%
1,408 $6,000
Q1 2021

May 13, 2021

BUY
$7.76 - $10.43 $26,477 - $35,587
3,412 New
3,412 $31,000

Others Institutions Holding DMAC

About DiaMedica Therapeutics Inc.


  • Ticker DMAC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 26,443,100
  • Market Cap $116M
  • Description
  • DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, develops treatments for neurological and kidney diseases. The company's lead drug candidate is DM199, a recombinant human tissue kallikrein-1 protein, which is in Phase 2 REDUX trial for the treatment of patients with moderate or severe chronic kidney disease caused by Type...
More about DMAC
Track This Portfolio

Track Barclays PLC Portfolio

Follow Barclays PLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

News

Stay updated on Barclays PLC with notifications on news.